|
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
|
14 January 2022 |
|
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
|
14 December 2021 |
|
GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
|
03 December 2021 |
|
GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
|
01 December 2021 |
|
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
|
19 November 2021 |
|
Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
|
15 November 2021 |
|
Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040
|
27 October 2021 |
|
GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine
|
06 October 2021 |
|
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
|
31 August 2021 |
|
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrates improved immune response and protection in preclinical study
|
18 August 2021 |